Ardelyx Announces FDA Plan to Convene Advisory Committee for XPHOZAH® (tenapanor)PRNewsWire • 04/25/22
Kyowa Kirin To Cut Royalty Payment Rate To Ardelyx For Tenapanor In Cardiorenal DisordersBenzinga • 04/11/22
Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2022 Spring Clinical MeetingsPRNewsWire • 04/07/22
Ardelyx Announces US Launch of IBSRELA®, a New First-in-Class Treatment for IBS-C in AdultsPRNewsWire • 04/04/22
Ardelyx, Inc. (ARDX) CEO Mike Raab on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/01/22
Ardelyx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent HighlightsPRNewsWire • 02/28/22
Ardelyx Announces $27.5 Million Debt Financing Agreement with SLR Capital PartnersPRNewsWire • 02/24/22
Ardelyx to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022PRNewsWire • 02/22/22
ARDELYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Ardelyx, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmBusiness Wire • 12/11/21